Strategic partnerships Orion Pharma is actively expanding European biosimilar commercialisation with IV pembrolizumab and nivolumab collaborations, presenting a clear channel for channel partners, distributors, and contract manufacturers to participate in high-demand oncology biosimilars.

Manufacturing expansion Significant investments exceeding EUR 100 million across Finnish sites (Espoo, Turku, Hanko, Oulu) through 2027–2030 create capacity and supply security, offering opportunities for co-development, contract manufacturing, and supply arrangements.

Pipeline momentum Active clinical programs including TEADES with ODM-212 and upcoming ASCO disclosures indicate a robust innovation engine, presenting opportunities to align strategic partnerships, licensing discussions, and early access collaborations around novel targets.

Integrated platforms A broad tech stack (Azure, Dynamics, Wrike, Jira, Adobe, etc.) and global operations suggest readiness for collaboration with digital health, data-sharing agreements, and joint ventures leveraging analytics, supply chain optimization, and scalable commercialization.

Public market potential EUR 1.89B net sales in 2025 and a disease-focused portfolio (oncology, pain, neurology) indicate sizable growth avenues in oncology biosimilars and high-value therapeutic areas, inviting strategic buyers, licensing partners, and distribution networks.